<DOC>
	<DOC>NCT01170091</DOC>
	<brief_summary>Safety and Effect of Mirapex(Pramipexole) tablet among Korean Restless Legs Syndrome Patients: An Open-Label, Postmarketing Surveillance Study</brief_summary>
	<brief_title>Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS</brief_title>
	<detailed_description>Study Design:</detailed_description>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criteria: 1. Moderate to severe Primary Restless Legs Syndrome 2. Male or female patients aged at least 18 years Exclusion criteria: 1. Any contraindications according to Basic Product Information (Company Core Data Sheet) or local Labelling; hypersensitivity to pramipexole or to any of the excipients. 2. Ongoing treatment with Mirapex 3. Pregnant and breastfeeding women 4. Concomitant pharmacologic treatment with other dopaminergic drugs(including Ldopa) 5. Secondary RLS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>